AngioDynamics Forecasts Fiscal Year 2025 Sales Of $282M-$288M, Representing Growth Of 4.2% – 6.4% Over Fiscal 2024 Pro Forma Revenue Of $270.7M Versus Consensus Of $287.68M

7/16/24 6:47:10 AM ET

$ANGO

Medical/Dental Instruments

Health Care

Get the next $ANGO alert in real time by email

Med Tech net sales are expected to grow in the range of 10% to 12%
Med Device net sales are expected to grow in the range of 1% to 3%
Gross margin to be approximately 52% to 53%
Adjusted EBITDA loss of $2.5 million to $0, compared to a pro forma adjusted EBITDA loss of $3.2 million in fiscal 2024

Get the next $ANGO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ANGO

Date	Price Target	Rating	Analyst
4/5/2024	$12.00	Perform → Outperform	Oppenheimer
9/25/2023	$19.00	Buy	H.C. Wainwright
4/17/2023	$14.00 → $13.00	Strong Buy → Outperform	Raymond James
10/15/2021	$28.00 → $37.00	Hold → Buy	Canaccord Genuity
8/20/2021		Perform	Oppenheimer
7/14/2021	$24.00 → $28.00	Hold	Canaccord Genuity
7/9/2021	$27.00 → $32.00	Strong Buy	Raymond James

More analyst ratings

$ANGO
Press Releases

Fastest customizable press release news feed in the world

AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System
Investigator initiated trial seeks to validate safety, efficacy of the NanoKnife System in treating targeted tumors while reducing or delaying need for radical intervention AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the launch of an international multi-center prospective registry study to assess the long term effects of treating men with unifocal intermediate-risk prostate cancer with the NanoKnife® System in partnership with the University College London Hospital (UCLH). Approximate
10/23/24 8:00:00 AM ET
$ANGO
Medical/Dental Instruments
Health Care
AngioDynamics Announces American Medical Association's CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver
New Codes Expand Market Access to Treatment with the NanoKnife® System AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that IRE has received CPT® Category I codes for the treatment of lesions in the prostate and liver. The decision by the American Medical Association's ("AMA") CPT® Editorial Panel will facilitate reimbursement for healthcare providers performing IRE ablation procedures and enables broader access to the NanoKnife System for patients. The new codes will be effective, with p
10/21/24 8:00:00 AM ET
$ANGO
Medical/Dental Instruments
Health Care
AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2025, which ended August 31, 2024. Fiscal Year 2025 First Quarter Highlights Quarter Ended August 31, 2024 Pro Forma* YoY Growth Net Sales $67.5 million 1.1% Med Tech Net Sales $28.0 million 8.7% Med Device Net Sales $39.5 million (3.6)% GAAP gross margin of 54.4% GAAP loss per share of $0.31 Adjusted loss per share of $0.11 Sub
10/3/24 6:30:00 AM ET
$ANGO
Medical/Dental Instruments
Health Care

AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2025, which ended August 31, 2024. Fiscal Year 2025 First Quarter Highlights Quarter Ended August 31, 2024 Pro Forma* YoY Growth Net Sales $67.5 million 1.1% Med Tech Net Sales $28.0 million 8.7% Med Device Net Sales $39.5 million (3.6)% GAAP gross margin of 54.4% GAAP loss per share of $0.31 Adjusted loss per share of $0.11 Sub
10/3/24 6:30:00 AM ET
$ANGO
Medical/Dental Instruments
Health Care
AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market open on Thursday, October 3, 2024. The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international). This conference call will also be webcast and can be accessed from the "Investors" section of the Angi
9/19/24 8:00:00 AM ET
$ANGO
Medical/Dental Instruments
Health Care
AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourth quarter and fiscal year 2024, which ended May 31, 2024. Fiscal Year 2024 Fourth Quarter Highlights Quarter Ended May 31, 2024 Pro Forma* YoY Growth Pro Forma* Net Sales $71.1 million 1.9% Med Tech Net Sales $29.3 million 11.3% Med Device Net Sales $41.8 million (3.8)% GAAP Gross margin of 54.3% GAAP loss per sh
7/16/24 6:30:00 AM ET
$ANGO
Medical/Dental Instruments
Health Care

AngioDynamics Announces Addition of Lorinda Burgess to Board of Directors
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced the appointment of Lorinda Burgess to the Company's Board of Directors. Ms. Burgess brings over 35 years of management, financial, and global operations experience, including over 15 years at Medtronic, Inc., where she was responsible for the company's Americas Region as CFO, Vice President of Finance. While at Medtronic, Ms. Burgess led optimization initiatives that drove operational efficiencies and significant cost reductions. "Ms
7/24/23 4:01:00 PM ET
$ANGO
Medical/Dental Instruments
Health Care
PAVmed Appoints Shaun O'Neil as Chief Operating Officer
PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid"), today announced the appointment of Shaun O'Neil to serve as Executive Vice President and Chief Operating Officer, overseeing diverse corporate operations and commercial activities across the Company and its subsidiaries. Mr. O'Neil has served as PAVmed's Chief Commercial Officer and Executive Vice President, Business Development since joining the Company in 2018. He will serve on the Company's Executive Committee and as an executive officer pursuant to Section 16(a) of the Securities
2/24/22 8:25:00 AM ET
$ANGO
$LUCD
$PAVM
Medical/Dental Instruments
Health Care
AVITA Medical, Inc. Appoints Two New Non-Executive Members to the Board of Directors
VALENCIA, Calif. and MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))) ("AVITA Medical"), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of James Corbett and Jan Stern Reed to its Board of Directors effective July 1, 2021. Mr. Corbett has approximately 40 years of leadership experience in the medical device field, most recently, as CEO of CathWorks Ltd., a software-based medical technology company. Mr. Corbett has extensive global commercial and operating experience, serving as an
6/1/21 4:01:00 PM ET
$SCL
$RCEL
$ANGO
Package Goods/Cosmetics
Consumer Discretionary
Medical/Dental Instruments
Health Care

AngioDynamics Forecasts Fiscal Year 2025 Sales Of $282M-$288M, Representing Growth Of 4.2% – 6.4% Over Fiscal 2024 Pro Forma Revenue Of $270.7M Versus Consensus Of $287.68M

Chat with this insight

Recent Analyst Ratings for $ANGO

$ANGO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

SVP Quality and Regulatory Nighan Warren Jr bought $5,285 worth of shares (868 units at $6.09), increasing direct ownership by 2% to 45,877 units (SEC Form 4)

EVP and CFO Trowbridge Stephen A bought $9,962 worth of shares (1,700 units at $5.86), increasing direct ownership by 0.99% to 172,711 units (SEC Form 4)

President and CEO Clemmer James C bought $120,600 worth of shares (20,000 units at $6.03), increasing direct ownership by 3% to 681,582 units (SEC Form 4)

$ANGO Market Insights

Live Market Insights

Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $13

HC Wainwright & Co. Reiterates Buy on AngioDynamics, Maintains $14 Price Target

Nasdaq Edges Lower; Morgan Stanley Earnings Top Views

$ANGO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SVP Quality and Regulatory Nighan Warren Jr bought $5,285 worth of shares (868 units at $6.09), increasing direct ownership by 2% to 45,877 units (SEC Form 4)

EVP and CFO Trowbridge Stephen A bought $9,962 worth of shares (1,700 units at $5.86), increasing direct ownership by 0.99% to 172,711 units (SEC Form 4)

President and CEO Clemmer James C bought $120,600 worth of shares (20,000 units at $6.03), increasing direct ownership by 3% to 681,582 units (SEC Form 4)

$ANGO Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by AngioDynamics Inc.

SEC Form SC 13G/A filed by AngioDynamics Inc. (Amendment)

SEC Form SC 13G/A filed by AngioDynamics Inc. (Amendment)

$ANGO SEC Filings

AngioDynamics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

SEC Form 10-Q filed by AngioDynamics Inc.

AngioDynamics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

$ANGO Press Releases

Fastest customizable press release news feed in the world

AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System

AngioDynamics Announces American Medical Association's CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver

AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results

$ANGO Financials

Live finance-specific insights

$ANGO Leadership Updates

Live Leadership Updates

$ANGO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results

AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024

AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results

AngioDynamics Announces Addition of Lorinda Burgess to Board of Directors

PAVmed Appoints Shaun O'Neil as Chief Operating Officer

AVITA Medical, Inc. Appoints Two New Non-Executive Members to the Board of Directors

AngioDynamics upgraded by Oppenheimer with a new price target

H.C. Wainwright initiated coverage on AngioDynamics with a new price target

AngioDynamics downgraded by Raymond James with a new price target

Recent Analyst Ratings for
$ANGO

$ANGO
Insider Purchases

$ANGO
Market Insights

$ANGO
Insider Trading

$ANGO
Large Ownership Changes

$ANGO
SEC Filings

$ANGO
Press Releases

$ANGO
Financials

$ANGO
Leadership Updates

$ANGO
Analyst Ratings